BIRC5 and neoplasm: Survivin is highly expressed in a variety of malignancies, and SurVaxM, the world’s first peptide mimetic oncology vaccine, works by stimulating T- and B-lymphocytes to target and inhibit survivin in tumor tissue where it is highly expressed.